Results 21 to 30 of about 104,861 (298)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

The Journal of Clinical Investigation, 2022
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations ...
Zhen Lu, Weiqun Mao, Hailing Yang, Janice M. Santiago-O’Farrill, Philip J. Rask, Jayanta Mondal, Hu Chen, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Yuanxin Xi, Kenta Masuda, Eli M. Carrami, Meng Chen, Yitao Tang, Lan Pang, David S. Lakomy, George A. Calin, Han Liang, Ahmed A. Ahmed, Hariprasad Vankayalapati, Robert C. Bast Jr.   +21 more
doaj   +1 more source

The potential role and application of PARP inhibitors in cancer treatment [PDF]

, 2009
Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core   +2 more sources

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status

Journal of Ovarian Research, 2023
As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment of ovarian cancer, the five-year survival rate of patients is still less
Yongsong Wu, Shilin Xu, Shanshan Cheng, Jiani Yang, Yu Wang   +4 more
doaj   +1 more source

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]

, 2016
Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide, Papa, Anselmo, Strudel, Martina, Tomao, Federica, Tomao, Silverio   +4 more
core   +2 more sources

Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo

EBioMedicine, 2016
The clinical potential of PARP-1 inhibitors has been recognized >10 years ago, prompting intensive research on their pharmacological application in several branches of medicine, particularly in oncology.
Colin Thomas, Yingbiao Ji, Niraj Lodhi, Elena Kotova, Aaron Dan Pinnola, Konstantin Golovine, Peter Makhov, Kate Pechenkina, Vladimir Kolenko, Alexei V. Tulin   +9 more
doaj   +1 more source

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data

Frontiers in Pharmacology, 2022
Background and purpose: poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have ...
Quanfeng Zhao, Pan Ma, Peishu Fu, Jiayu Wang, Jiayu Wang, Kejing Wang, Kejing Wang, Lin Chen, Lin Chen, Yang Yang, Yang Yang   +10 more
doaj   +1 more source

PARP inhibitors and more

Journal of the Turkish German Gynecological Association, 2015
Polyadenosine diphosphate (ADP) ribose polymerase (PARP) lends a panoramic view to the inner mystery of protection of integrity of deoxyribonucleic acid (DNA) in a cell genome. They are a balancing part of an even more dynamic equilibrium of normalcy against daily assaults.
Chinmoy K, Bose, Nirban, Basu
openaire   +2 more sources

PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]

, 2015
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T, BENEDETTI PANICI, PIERLUIGI, CASORELLI, ASSUNTA, DI DONATO, VIOLANTE, DOMENICI, LAVINIA, GASPARRI, MARIALUISA, IMPERIALE, LUDOVICA, MARCHETTI, CLAUDIA, MONTI, Marco, MUSELLA, ANGELA, MUZII, LUDOVICO, PALAIA, INNOCENZA, PECORINI, Francesco, RUSCITO, ILARY, SALERNO, LAURA   +14 more
core   +1 more source

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]

, 2017
Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don, Brown-Swigart, Lamorna, Buxton, Meredith, DeMichele, Angela, Esserman, Laura, Glas, Annuska, Hirst, Gillian, Hylton, Nola, Linn, Sabine, Olopade, Olufunmilayo, Paoloni, Melissa, Petricoin, Emanuel, Rugo, Hope, Sanil, Ashish, Severson, Tesa M, Symmans, Fraser, van 't Veer, Laura, Wolf, Denise M, Wulfkuhle, Julia, Yau, Christina, Yee, Doug   +20 more
core   +2 more sources

The suppression of DNA repair induced by PARP-1 inhibitors rucaparib and olaparib in combination with the radiopharmaceutical 131I-MIBG in noradrenaline transporter-expressing xenograft tumors [PDF]

, 2018
No abstract ...
Gaze, Mark N., Mairs, Robert J., Nile, Donna L., Nixon, Colin, Rae, Colin   +4 more
core   +1 more source